LC
PTCT icon

Lindbrook Capital’s PTC Therapeutics PTCT Stock Holding History

Lindbrook Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$31.6K Buy
620
+24
+4% +$1.2K ﹤0.01% 1165
2024
Q4 		$26.9K Hold
596
– – ﹤0.01% 1115
2024
Q3 		$22.1K Sell
596
-30
-5% -$1K ﹤0.01% 1241
2024
Q2 		$19.1K Buy
626
+105
+20% +$3.4K ﹤0.01% 1268
2024
Q1 		$15.2K Hold
521
– – ﹤0.01% 1357
2023
Q4 		$14.4K Buy
521
+492
+1,697% +$11.3K ﹤0.01% 1352
2023
Q3 		$650 Buy
29
+11
+61% +$409 ﹤0.01% 2465
2023
Q2 		$732 Buy
18
+10
+125% +$489 ﹤0.01% 2429
2023
Q1 		$388 Buy
8
+4
+100% +$183 ﹤0.01% 2651
2022
Q4 		$153 Sell
4
-36
-90% -$1.5K ﹤0.01% 2774
2022
Q3 		$2K Buy
40
+21
+111% +$1.03K ﹤0.01% 2121
2022
Q2 		$1K Sell
19
-4
-17% -$140 ﹤0.01% 2336
2022
Q1 		$1K Buy
+23
New +$886 ﹤0.01% 2330
2021
Q2 		– Sell
-16
Closed -$1K – 1987
2021
Q1 		$1K Buy
+16
New +$950 ﹤0.01% 1773

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's PTCT Position: Q1 2025 in Review

Lindbrook Capital increased its PTC Therapeutics (PTCT) stake by 4% in Q1 2025, buying an estimated $1.2K and bringing the position to 620 shares worth $31.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

Lindbrook Capital first reported a position in PTCT in Q1 2021 and has held it in 14 quarters since. 261 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

  • Lindbrook Capital held 620 shares of PTC Therapeutics worth $31.6K as of Q1 2025.
  • Lindbrook Capital bought 24 PTC Therapeutics shares in Q1 2025, an estimated $1.2K.
  • PTC Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1165 holding.
  • Lindbrook Capital first reported a position in PTC Therapeutics in Q1 2021 and has held it in 14 quarters since.
  • 261 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.